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It is suggested that subtyping of complex inflammatory diseases can be based on genetic
susceptibility and relevant environmental exposure (G+E). We propose that using matched
cellular phenotypes in human subjects and corresponding preclinical models with the same
G+E combinations is useful to this end. As an example, defective Paneth cells can subtype
Crohn’s disease (CD) subjects; Paneth cell defects have been linked to multiple CD
susceptibility genes and are associated with poor outcome. We hypothesized that CD
susceptibility genes interact with cigarette smoking, a major CD environmental risk factor, to
trigger Paneth cell defects. We found that both CD subjects and mice with ATG16L1T300A
(T300A; a prevalent CD susceptibility allele) developed Paneth cell defects triggered by
tobacco smoke. Transcriptional analysis of full-thickness ileum and Paneth cell–enriched
crypt base cells showed the T300A-smoking combination altered distinct pathways,
including proapoptosis, metabolic dysregulation, and selective downregulation of the
PPARg pathway. Pharmacologic intervention by either apoptosis inhibitor or PPARg agonist
rosiglitazone prevented smoking-induced crypt apoptosis and Paneth cell defects in T300A
mice and mice with conditional Paneth cell–specific knockout of Atg16l1. This study
demonstrates how explicit G+E can drive disease-relevant phenotype and provides rational
strategies for identifying actionable targets.
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Introduction
Subtyping of complex immune diseases, such as inflammatory 
bowel disease (IBD), has traditionally been done by categorizing 
clinical phenotypes and disease presentations (1, 2). Incorporat-
ing key pathogenic elements, namely genetic susceptibility and 
relevant environmental exposure (G+E) (3), into subclassification 
schemes may facilitate identification of therapeutic targets in 
these subtypes. The identification of more than 200 susceptibility 
SNPs and recently identified prognosis-associated SNPs (4, 5) for 
Crohn’s disease (CD), one major form of IBD, poses a challenge to 
this approach, as many of these SNPs have been associated with 
gene expression and functional changes in various cell types, such 
as immune (6–9) and epithelial cells (10, 11). While development 
of gene scores has shown promise in subtyping patients (12), such 
scores do not account for environmental exposures that are likely 
to trigger phenotypes and disease. Likewise, environmental factors 
identified by epidemiologic studies require relevant and functional 
testing in preclinical models where exposure to these environmen-
tal factors is controlled. Conversely, environmental factors identi-
fied in preclinical models need to be confirmed in patients.
Development of a surrogate phenotype/biomarker that can 
integrate the effects from both genetics and environmental fac-
tors will facilitate subtyping of IBD. In CD, morphologic patterns 
of small intestinal Paneth cells (Paneth cell phenotype) are a sur-
rogate phenotype that stratifies CD into prognostically distinct 
subtypes (13–15). We and others have shown that, in mouse mod-
els, knockout of CD-associated genes (Atg16l1, Xbp1, Irgm, Lrrk2) 
resulted in Paneth cell defects manifested as secretory granule 
abnormalities (11, 16–18) that are similar to those observed in CD 
subjects (11, 14, 15), with potential additive effects between genes 
(14). We previously showed that administration of a chronic strain 
of murine norovirus (MNV) could induce Paneth cell defects in 
Atg16l1HM (hypomorph) mice, which express low levels of Atg16l1 
protein (19). In human subjects, Paneth cell defects in CD are 
associated with microbiota changes (20) and poor clinical out-
come (14, 15). Thus, Paneth cell phenotypes are biologically and 
clinically relevant surrogate phenotypes ideally suited for mech-
anistic studies and identification of potential therapeutics in CD.
One G+E trigger for Paneth cell defects in mouse models, 
MNV (19), as yet has no correlate in human subjects (21, 22). 
Therefore, our goal was to identify an environmental trigger for 
Paneth cell defects that occurs in both CD subjects and analo-
gous mouse models. Among the known CD environmental risk 
factors (1, 23), cigarette smoking is one of the most reproducible 
(23, 24). It is also associated with an aggressive disease course 
in patients with established CD (25). A recent study suggested 
potential interactions between genetics and cigarette smoking 
(26). Based on these findings, we hypothesized that smoking 
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ure 1A). In addition, CD subjects who were of the ATG16L1T300A 
genotype and who were also smokers (T300A-smoking group) 
showed significantly shorter time to recurrence after surgery 
(Supplemental Figure 2). We therefore hypothesized that cigarette 
smoking was a trigger for Paneth cell defects in CD subjects. Giv-
en that the most common risk allele for CD susceptibility known 
to be associated with Paneth cell defects was ATG16L1T300A (11), 
we further hypothesized that smoking triggers Paneth cell defects 
preferentially in CD subjects who harbored the ATG16L1T300A risk 
allele(s). In support of this hypothesis, the ATG16L1T300A genotype 
in CD subjects who were smokers was associated with a lower 
percentage of normal Paneth cells, whereas subjects with no-risk 
(NR) allele were not (Figure 1, B and C, and Supplemental Table 
2). We have previously described several distinct classes of abnor-
mal Paneth cell morphology (14, 27). We determined the distri-
bution of each subclass of abnormal Paneth cells and found that 
the majority of the abnormal Paneth cells were of the D2 subclass 
(decreased granules) (Supplemental Figure 3); this was similar to 
previous findings in adult CD (14, 15, 27). None of the individual 
abnormal morphology subclasses showed a significantly different 
distribution across the groups; rather, the sum percentage of these 
abnormal classes (or conversely, the percentage of normal Paneth 
would induce Paneth cell defects in genetically susceptible CD 
patients. As a proof of concept, we investigated the correlation 
of smoking exposure, Paneth cell defects, and postoperative 
recurrence after ileal/ileocolonic resections in CD subjects with 
ATG16L1T300A, the most prevalent CD susceptibility SNP in White 
patients (4). We then performed functional studies using the 
Atg16l1T300A mouse model to identify host factors that mediated 
smoking-induced Paneth cell defects. Finally, we validated ratio-
nally designed therapeutic strategies targeting these factors that 
result in Paneth cell defects.
Results
CD subjects with ATG16L1T300A were susceptible to smoking-associated 
Paneth cell defects. We found that in CD subjects (demograph-
ics described in Supplemental Table 1; supplemental materi-
al available online with this article; https://doi.org/10.1172/
JCI120453DS1) who received ileocolonic anastomosis and post-
operative immunomodulatory and/or biologics prophylactic ther-
apy (a known confounder for outcome; n = 128), smoking status 
and Paneth cell phenotype were prognosticators of recurrence 
(Supplemental Figure 1) and the combination of these factors fur-
ther stratified patients into prognostically distinct subgroups (Fig-
Figure 1. CD subjects with ATG16L1T300A genotype (T300A) were more susceptible to cigarette smoking–associated Paneth cell defects. (A) In a cohort of 
CD subjects (n = 186) who underwent ileocolectomy, 126 received postoperative prophylaxis. Within this prophylaxis subset, smokers with type I Paneth 
cell phenotype (<80% Paneth cells with normal granule morphology) showed the shortest time to disease recurrence (P = 0.0183 by log-rank test). (B) 
Representative HD5 immunofluorescence. Scale bar: 10 μm. Asterisks indicate abnormal Paneth cells. (C) Cigarette smoking was associated with lower 
percentage of normal Paneth cells in patients with ATG16L1T300A allele or alleles, while no significant differences in Paneth cell defects were seen between 
NR patients with or without smoking history (overall P =0.001). NR-nonsmoking, n = 25; NR-smoking, n = 14; T300A-nonsmoking, n = 84; T300A-smoking, 
n = 62. Data were analyzed by Kruskal-Wallis test followed by Dunn’s multiple comparison tests between groups and represent mean ± SEM. P values for 
comparisons between groups are shown in Supplemental Table 2. *P < 0.05; **P < 0.01. 
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(but not 2 weeks) were required to restore normal Paneth cell mor-
phology (Figure 2D). Therefore, Paneth cell defects in Atg16l1T300A 
mice after short-term smoking exposure were reversible upon 
smoking cessation.
We also determined whether administration of nicotine, a 
major component in cigarettes, would elicit similar effects on 
Paneth cells. We administered a daily dose of nicotine (0.7 mg/
mouse/d) to mice instead of cigarette smoke. This dose is greater 
than the predicted absorbed nicotine dose (approximately 0.42 
mg/mouse/d) achieved in the cigarette-smoking experiments 
based on the nicotine content of the cigarettes and known absorp-
tion kinetics (29, 30). Surprisingly, nicotine administration did not 
induce Paneth cell defects or crypt base apoptosis in Atg16l1T300A 
mice (Supplemental Figure 8).
Gut microbiota did not alter smoking-induced Paneth cell defects. 
Paneth cell function is important for maintaining the homeostasis of 
the gut microbial community (31–33), and dysbiosis can develop as 
a downstream effect of Paneth cell defects or loss (20, 34, 35). Thus, 
we examined whether microbiota changes occurred upstream of or 
as part of a feedback loop with Paneth cell defects in the context of 
G+E. We first compared the microbial compositions in Atg16l1T300A 
mice and littermates with and without smoking. There was no sig-
nificant difference in microbial composition between Atg16l1T300A 
mice and littermates without smoking (Supplemental Figure 9A). 
Smoking did not result in significant changes in α (Supplemental 
Figure 9, B and C) or β diversity (Supplemental Figure 9, D and E) in 
either Atg16l1T300A mice or littermates. Deeper examination of spe-
cific microbial taxa showed only limited differences between the 
groups of mice. For example, smoking induced relatively increased 
abundance of Lactobacillales and Turicibacterales and reduced 
the abundance of Alphaproteobacteria and Betaproteobacteria in 
Atg16l1T300A mice, whereas it only increased the abundance of Corio-
bacterales and Turicibacterales in the WT littermates (Supplemental 
Figure 9, F and G). Therefore, smoking only modestly altered the 
composition of the gut microbiota, regardless of genotype.
Because we did detect small differences in the microbiota 
composition that depended on smoking in Atg16l1T300A mice, we 
functionally tested the microbiota for its ability to induce Paneth 
cell defects. We cohoused Atg16l1T300A mice and WT littermates 
exposed to smoking (microbiota donors) with mice of the same 
genotypes not exposed to smoking (microbiota recipients) (Fig-
ure 3A). Recipients were pretreated with antibiotics (36) to allow 
successful colonization of donor microbiota. The recipients 
showed microbiota compositions indistinguishable from those of 
their respective donors after 4 weeks (Supplemental Figure 10). 
Cohousing of donors and recipients did not induce Paneth cell 
defects in Atg16l1T300A recipients (Figure 3B). Therefore, the lim-
ited differences in microbial composition observed with smoking 
in the Atg16l1T300A mice did not contribute to Paneth cell defects.
Smoking-induced Paneth cell phenotype did not correlate with 
lung or systemic inflammation. To determine whether Paneth cell 
defects could be due to secondary changes of lung and/or sys-
temic inflammation, we further examined the lungs for histopa-
thology and serum for inflammatory markers. No overt inflam-
mation was seen in the lungs in any of the mice (Supplemental 
Figure 11), consistent with a previous report that longer smoking 
exposure may be required to elicit lung inflammation (37). Like-
cells) provided the most robust association in the T300A-smoking 
group (Figure 1C).
Given that NOD2 is the other CD susceptibility gene known 
to be associated with Paneth cell defects in North American CD 
cohorts (14), we also examined the correlation among common 
NOD2 variant (R702W, G908R, and L1007fs) carrier status, smok-
ing status, and Paneth cell phenotype. There were no significant 
changes in the percentage of normal Paneth cells in subjects car-
rying NOD2 variants that were smokers (Supplemental Figure 
4A). We further correlated the total numbers of ATG16L1T300A and 
NOD2 risk alleles, smoking status, and Paneth cell phenotype. 
There was no significant difference in the genetic burden regard-
ing Paneth cell phenotype and smoking status (Supplemental Fig-
ure 4B). Therefore, smoking-induced Paneth cell defect correlated 
specifically with ATG16L1T300A alleles in this cohort.
Atg16l1T300A mice were susceptible to smoking-induced Paneth 
cell defects. We modeled the 4 patient populations above in a 
mouse model representative of the G+E interactions by expos-
ing Atg16l1T300A mice (28) and WT littermates to cigarette smoke 
for 4 weeks (Figure 2A). Paneth cell defects were triggered only 
in the Atg16l1T300A mice (Figure 2B and Supplemental Table 3), 
recapitulating the findings in CD subjects. We also examined the 
distribution of each class of abnormal Paneth cells. In observa-
tions similar to those in the human cohort, the abnormal Paneth 
cells were predominantly of the D2 subclass, with a small per-
centage of D3 subclass (diminished) (Supplemental Figure 5A). 
Increased percentages of these 2 subclasses of abnormal Paneth 
cells were largely responsible for the decreased percentage of 
normal Paneth cells in the T300A-smoking group (Supplemental 
Figure 5, B–D).
We also performed transmission electron microscopy (TEM) 
to investigate potential ultrastructural changes in Paneth cells. We 
found that Paneth cells of the T300A mice contained cytoplasmic 
vesicles and degenerative mitochondria (Supplemental Figure 6, 
A–C), which was similar to our previous observations in Atg16l1HM 
mice (11). Importantly, these changes were more frequent in 
T300A mice exposed to smoking compared with those that were 
not (Supplemental Figure 6D). Paneth cells from CD patients that 
were of the ATG16L1T300A genotype and smokers also possessed 
similar features (Supplemental Figure 6, E and F). To exclude the 
possibility that the Paneth cell defects in the T300A-smoking mice 
were the result of stress associated with the physical presence in 
the smoking chamber rather than exposure to cigarette smoke, 
T300A mice were placed in the smoking chamber and exposed 
to normal air pumped through the machine (i.e., no exposure to 
cigarette smoke). Physical presence in the smoking chamber alone 
with exposure to normal air did not result in Paneth cell defects in 
these mice (Supplemental Figure 7).
We next altered the duration of smoking to determine the 
impact on Paneth cell phenotypes. We found that a 2-week expo-
sure was sufficient to trigger Paneth cell defects in Atg16l1T300A 
mice, but that exposure beyond 2 weeks did not increase the per-
centage of defective Paneth cells (Figure 2C). We also tested the 
durability of smoking-induced Paneth cell defects. Paneth cell phe-
notype was examined in Atg16l1T300A mice at the end of a 4-week 
smoking period (baseline), followed by a 2- or 4-week washout 
period where smoking was discontinued. Four weeks of washout 
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percentages of normal Paneth cells between MNV-uninfected and 
MNV-infected mice (Supplemental Figure 13). Therefore, natural 
MNV infection was an unlikely cause for the Paneth cell defects 
observed in this study.
Smoking and Atg16l1T300A genotype interaction led to unique 
host transcriptomic changes. The lack of a causative link among 
the microbiota, systemic inflammatory markers, and Paneth cell 
defects indicates that the underlying mechanisms most likely 
stemmed from the host intestine per se. To comprehensively 
analyze the effect of G+E in all ileal cell types, we performed 
global RNA sequencing (RNA-seq) using mRNAs isolated from 
full-thickness ileal sections from Atg16l1T300A mice and WT litter-
mates with or without smoking. Identified transcriptomic differ-
ences were categorized as associated with either genetics (G pat-
terns), smoking (E patterns), or combinatorial effects of genetics 
and smoking (G+E patterns) (Supplemental Figure 14A).
wise, none of the samples showed detectable TNF-α in serum 
(Supplemental Figure 12A). In addition, there was no significant 
difference in serum myeloperoxidase, RAGE, CXCL1, CXCL2, 
IL-6, or IL-1β levels among the groups (Supplemental Figure 12, 
B–G). Therefore, there was no correlation between lung or sys-
temic inflammation and G+E-associated Paneth cell defects.
Natural MNV infection was an unlikely cause for smoking- 
induced Paneth cell defects. We previously showed that admin-
istration of a chronic strain of MNV could induce Paneth 
cell defects in Atg16l1HM mice (19). To exclude the possibili-
ty that natural MNV infection, not infrequently encountered 
in animal facilities (19), could result in Paneth cell defects in 
Atg16l1T300A mice exposed to smoking, we also determined the 
MNV titers in fecal samples. We found that 16% of mice were 
indeed infected with MNV. However, among the Atg16l1T300A mice 
exposed to smoking, there was no significant difference in the 
Figure 2. Atg16l1T300A mice were more susceptible to Paneth cell defects after exposure to cigarette smoking. (A) Schematic illustration of experimental 
design. Atg16l1T300A (T300A) mice and WT littermates were treated with or without cigarette smoking for 4 weeks, and Paneth cell morphology was assessed. 
(B) Smoking induced more Paneth cell defects, specifically in Atg16l1T300A mice (overall P < 0.0001). (A and B) WT-nonsmoking, n = 12; WT-smoking, n = 21; 
T300A-nonsmoking, n = 19; T300A-smoking, n = 25. Results are from 6 independent experiments. Data were analyzed by 2-way ANOVA. (C) Two weeks of 
cigarette smoking was sufficient to induce Paneth cell defects in Atg16l1T300A mice (P = 0.0054), while no additional Paneth cell defects were seen with longer 
exposure time, up to 6 weeks (P > 0.9999). Nonexposed, n = 17; 2 weeks, n = 10; 4 weeks, n = 10. (D) After 4 weeks of cessation of cigarette exposure, the 
percentage of normal Paneth cells of the Atg16l1T300A mice returned to a level comparable to that of unexposed status (P = 0.0027). Baseline, n = 6; 2 weeks, 
n = 7; 4 weeks, n = 7. (C and D) Data were analyzed by 1-way ANOVA, followed by Mann-Whitney U tests between groups. *P < 0.05; **P < 0.01; ***P < 0.001; 
****P < 0.0001. (B–D) Data represent mean ± SEM.
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The G+E patterns could be further classified into T300A- 
smoking and WT-smoking patterns (Figure 4, A and B, and Supple-
mental Figure 13, B–E). The T300A-smoking pattern was striking, 
as it included signatures associated with the promotion of apop-
tosis and the downmodulation of insulin signaling, predominant-
ly through Ppara/g regulation (Figure 4A, Supplemental Figure 
14, B–E, and Supplemental Table 4). Interestingly, Pparg activity 
has been shown to modulate Paneth cell function during high- 
fat–diet exposure (38).
The WT-smoking pattern included induction of genes associ-
ated with Hnf4α and Ppar regulation in addition to lipid and amino 
acid metabolism (Figure 4B, Supplemental Figure 14F, and Sup-
plemental Table 5). These molecular responses to smoking were 
either attenuated or not activated in the Atg16l1T300A mice.
The G patterns specific to the Atg16l1 T300A ileum included 
genes that function in metabolism and complement activation (Fig-
ure 4C, Supplemental Figure 14, G and H, and Supplemental Table 
6). We had previously found that deletion of Atg16l1 in mouse intes-
tinal epithelial cells targets metabolism and acute-phase reactants 
such as complement (11). The E patterns enriched with smoking 
included genes that function in cell death, IFN signaling, cycloox-
ygenase pathway, and gluconeogenesis (Figure 4D, Supplemental 
Figure 14, I and J, and Supplemental Tables 7 and 8). Of note, smok-
ing can induce apoptosis in a mouse model of emphysema (39).
Figure 3. Smoking-associated Paneth cell defects in Atg16l1T300A mice 
were not horizontally transmissible by cohousing. (A) Schematic illustra-
tion of experimental design. Smoking Atg16l1T300A mice and WT litter-
mates were used as microbiota donors and cohoused with nonsmoking, 
antibiotic-pretreated mice of the same genotypes as recipients. Cohousing 
lasted 4 weeks, during which the donors continued to receive exposure to 
cigarette smoking. (B) The Paneth cell defects of the Atg16l1T300A microbi-
ota donor mice did not transfer to recipient mice. WT donors, n = 5; WT 
recipients, n = 15; T300A donors, n = 5; T300A recipients, n = 17. Data ana-
lyzed by Kruskal-Wallis test followed by Dunn’s multiple comparison tests 
between groups. *P < 0.05; **P < 0.01. Data represent mean ± SEM.
Apoptosis was a central mechanism behind smoking-associated 
Paneth cell defects in CD subjects and mice with ATG16L1T300A. The 
analysis of the transcriptomics data suggested that apoptosis- 
associated cell death might be a critical mediator of G+E- 
induced Paneth cell defects. We found that in CD subjects, 
the highest level of crypt base apoptosis was present in 
Atg16l1T300A-smoking as compared with all other groups (Figure 
5A, Supplemental Figure 15A, and Supplemental Table 2). Fur-
ther analysis showed that Paneth cells themselves were sensi-
tive to apoptosis in ATG16L1T300A-smoking through defensin 5 
(HD5)/TUNEL colocalization (Figure 5B and Supplemen-
tal Table 2). In addition, ATG16L1T300A-smoking, but not NR- 
smoking, also had lower Paneth cell numbers/crypt (Figure 5C 
and Supplemental Table 2). The effects of smoking and geno-
type showed no detectable effect on crypt proliferation, the 
other major function of epithelial cells in the crypt base (Supple-
mental Figure 16, A and B, and Supplemental Table 2).
Atg16l1T300A mice exposed to smoking also showed increased 
crypt apoptosis (Figure 5D, Supplemental Figure 15B, and Sup-
plemental Table 3) and specifically increased Paneth cell apop-
tosis (Figure 5E and Supplemental Table 3), confirming that 
apoptosis-associated cell death in the crypt base compartment 
was directly linked to smoking-induced Paneth cell defects. Of 
note, the Paneth cells that coexpressed cleaved caspase-3 and 
lysozyme were exclusively of the abnormal morphology (human: 
92% D2, 8% D3; mouse: 97% D2, 3% D3). Atg16l1T300A mice 
exposed to smoking tended to have fewer Paneth cells as com-
pared with smoking WT littermate controls (WT-smoking), but 
this was not significant (Figure 5F and Supplemental Table 3). 
We also found that smoking did not induce apoptosis in villus 
epithelial cells (Figure 5G and Supplemental Figure 15C), fur-
ther demonstrating that smoking and genotype specifically affect 
Paneth cells. Finally, crypt proliferation was not altered by expos-
ing mice of either genotype to smoke (Supplemental Figure 16, C 
and D, and Supplemental Table 3). Therefore, crypt base apopto-
sis was a specific response to G+E, and the process did not elicit 
compensatory alterations in proliferation. To determine wheth-
er apoptosis mediated the smoking-induced Paneth cell defects 
in Atg16l1T300A mice, we administered pan-caspase inhibitor 
carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylke-
tone (Z-VAD-FMK) to the Atg16l1T300A mice. Z-VAD-FMK prevented 
the Paneth cell defects (Figure 5H) and crypt apoptosis (Figure 
5I) induced by smoking, confirming that apoptosis is upstream of 
Paneth cell defects. In addition, we also determined the poten-
tial role of necroptosis in mediating Paneth cell defects (40), as a 
recent report has suggested a link between Atg16l1 and necropto-
sis (41). Administration of the necroptosis inhibitor nec-1 did not 
prevent the Paneth cell defect (Supplemental Figure 17A) nor crypt 
base apoptosis (Supplemental Figure 17B) phenotypes in T300A- 
smoking mice, confirming the lack of association with necroptosis 
in this experimental design.
Repressed Pparg activation resulted in smoking-induced crypt 
apoptosis and Paneth cell defects. The unique G+E patterns in the 
full-thickness ileal transcriptomic analysis demonstrated an atten-
uation or repression of Ppara/g activation in the Atg16l1T300A mice 
exposed to smoking as compared with WT animals (Supplemental 
Figure 14, C–E, Supplemental Table 9). These data suggested the 
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possibility that Ppara/g activation in WT-smoking mice may be 
protective of the normal Paneth cell phenotype. In a subsequent 
analysis of the G+E patterns using Enrichr to probe the GEO drug 
perturbations data sets (refs. 42, 43, and Supplemental Figure 
18A), the WT-smoking pattern genes uniquely matched com-
pounds with multiple highly significant adjusted P value entries 
(adjusted P < 0.01) (Supplemental Figure 18B). The analysis 
revealed that selective PPARγ agonists, including rosiglitazone, 
pioglitazone, and troglitazone (especially among the drug-like 
molecules) regulate the genes in this potentially protective pattern, 
whereas fibrates (PPARα agonists) were not detected in this anal-
ysis. This suggested the general Ppara/g signature observed in the 
pathway-level analysis may be more specific to Pparg.
To further justify analysis of this pathway in Paneth cells, we 
performed global transcriptional analysis of crypt base mate-
rial (enriched for Paneth cells) from these mice collected by 
laser capture microdissection (LCM) (Figure 6A). We found that 
Atg16l1T300A mice exposed to smoking showed significantly dimin-
ished expression of many Pparg-associated genes as compared with 
the other groups of mice in this experiment (Figure 6B and Sup-
plemental Table 10). We also found a similar enrichment of down-
regulated PPARγ pathway genes in 2 specific G+E groups from our 
previous LCM-procured Paneth cell data sets: (a) Atg16l1HM mice 
infected with MNV (ref. 19, Figure 6B, and Supplemental Table 
11), and importantly, (b) CD subjects who were smokers and of 
the ATG16L1T300A genotype (ref. 14, Figure 6B, and Supplemental 
Table 12). These data collectively suggest that the PPARγ pathway 
is a central mechanism closely linked to Paneth cell defects in CD 
subjects and relevant mouse models as a result of G+E interaction.
We next functionally tested the role of the PPARγ pathway 
in smoking-induced Paneth cell defects. Administration of the 
PPARγ agonist rosiglitazone rescued the smoking-induced Paneth 
cell defects (Figure 6C) and crypt base apoptosis (Figure 6D) in 
the Atg16l1T300A mice. In parallel, we also generated mice with 
intestinal epithelium–specific Pparg deletion (Pparg/Villin-Cre 
mice). These mice showed reduced percentages of normal Paneth 
cells, reduced Paneth cell numbers/crypt, and increased crypt 
base apoptosis compared with the Ppargfl/fl littermate controls 
(Supplemental Figure 19). Therefore, the PPARγ pathway is a criti-
cal mediator of crypt apoptosis and Paneth cell defects.
G+E interactions directly affected Paneth cells and precursors. 
The crypt base transcriptomic data also suggested that the G+E 
Figure 4. G+E interactions resulted in unexpected transcriptomic findings. Unique transcriptomic patterns associated with (A and B) combination from 
both genetics and smoking interactions (G+E patterns), (C) genetics alone (G patterns), or (D) smoking exposure alone (E patterns). Full-thickness ileum 
from Atg16l1T300A mice and WT littermates with or without cigarette smoking exposure was analyzed by RNA-seq. The x axes in all panels represent log P 
values. Significantly enriched pathways are shown.
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Figure 5. Paneth cell defects were mediated by apoptosis. (A) Smoking was associated with more crypt base apoptosis in CD subjects with the Atg16l1T300A 
genotype (P < 0.0001), compared with NR subjects (P > 0.9999). (B) Smoking was associated with more apoptotic Paneth cells in CD subjects with ATG16L1T300A 
(P = 0.01) compared with NR subjects (P > 0.9999). (C) ATG16L1T300A subjects who were smokers had reduced Paneth cell numbers/crypt (P = 0.0103) compared 
with NR subjects (P > 0.9999). (A–C) Sample sizes and data analysis were as in Figure 1. (D) In mice, smoking induced more profound crypt base apoptosis 
specifically in Atg16l1T300A mice (P < 0.0001). (E) More Paneth cells were undergoing apoptosis in Atg16l1T300A mice exposed to cigarette smoking (P = 0.0018). (F) 
Smoking did not induce significant alterations in Paneth cell numbers/crypt, irrespective of genotype (P = 0.0948). (G) Smoking did not induce increased apop-
tosis in the villi, irrespective of genotype (P = 0.5058). (D–G) Sample sizes and data analysis were as in Figure 2. Pan-caspase inhibitor Z-VAD-FMK administra-
tion prevented smoking-induced (H) Paneth cell defects and (I) crypt base apoptosis in Atg16l1T300A mice. (H and I) Control, n = 8; pan-caspase inhibitor, n = 10; 
nonsmoking, n = 7. Data were analyzed by Kruskal-Wallis tests followed by Dunn’s multiple comparison tests between groups. *P < 0.05; **P < 0.01,  
***P < 0.001; ****P < 0.0001. Data represent mean ± SEM.
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although we cannot exclude Paneth cell–independent mecha-
nisms with certainty.
TNF antagonism rescued smoking-induced Paneth cell defects. 
We previously suggested that TNF-α, a major therapeutic tar-
get in CD, may be an important mediator of Paneth cell defects 
in CD subjects (15). We have also shown that anti–TNF-α treat-
ment can ameliorate the intestinal pathology in Atg16l1HM mice 
infected with MNV and treated with dextran sodium sulfate 
(DSS) (19). Interestingly, it has also been shown that PPARγ 
antagonism in preadipocytes conferred increased sensitivity to 
TNF-α–induced apoptosis (45) and that treatment with PPARγ 
agonist blocked TNF-α–induced apoptosis in vitro (46), suggest-
ing that a defective PPARγ pathway could prime the host tissue to 
TNF-α–induced apoptosis. In Atg16l1T300A mice, anti–TNF-α treat-
interaction induced effects directly on Paneth cells themselves. 
To test this hypothesis in vivo, we utilized a conditional knock-
out model in which Atg16l1 was deleted exclusively in Paneth cells 
(α-defensin-4-IRES-Cre Atg16l1fl/fl mice; herein termed PC-Cre+ 
mice) (44). As seen in Supplemental Figure 20A, the PC-Cre+ 
mice elicited Paneth cell defects when exposed to cigarette smok-
ing, whereas Atg16l1fl/fl mice (herein termed PC-Cre– mice) did 
not, as expected. The PC-Cre+ mice also showed increased crypt 
base apoptosis (Supplemental Figure 20B) and increased Paneth 
cell apoptosis (Supplemental Figure 20C). Finally, rosiglitazone 
administration also prevented smoking-induced Paneth cell 
defects and crypt apoptosis in PC-Cre+ mice (Figure 6, E and F). 
These data further support the notion that the G+E effect can act 
directly on Paneth cells and their Defa4-expressing precursors, 
Figure 6. Pparg-associated metabolism dysregulation 
resulted in crypt base apoptosis and Paneth cell defects. 
(A) Workflow for Paneth cell LCM of the mice in the 
T300A-smoking study. (B) Significantly downregulated 
Pparg-associated genes were found in all 3 data sets, 
including the Atg16l1T300A-smoking mice (n = 108 genes), 
Atg16l1HM MNV-infected mice (n = 298 genes), and CD 
subjects that were ATG16L1T300A-smokings (n = 166 genes). 
Adjusted P value for each group (by ChEA, https://omic-
tools.com/chea-tool): #P = 0.0044; ##P = 0.0004; ###P 
= 0.038. Ppar-γ agonist rosiglitazone (Rosi) treatment 
rescued (C) Paneth cell defects (P < 0.0001) and (D) crypt 
base apoptosis (P < 0.0001) in Atg16l1T300A mice exposed 
to cigarette smoking. (C and D) Total n = 9/group for non-
smoking groups; n 0/group for smoking groups. Rosiglita-
zone administration prevented the (E) Paneth cell defects 
and (F) crypt apoptosis of PC-Cre+ smoking mice (n = 4/
group). (C–E) Statistical analysis was performed using 
2-way ANOVA. *P < 0.05, ****P < 0.0001. Data represent 
mean ± SEM.
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notype as a unique readout to functionally test potential genetic 
and environmental interactions. We also show that the G+E inter-
actions resulted in previously unpredicted intestinal metabolic 
dysregulation, leading to crypt base apoptosis and Paneth cell 
defects mediated by PPARγ that could additionally be blocked 
by anti–TNF-α (Figure 8B). Finally, we show that the G+E inter-
actions directly affect Paneth cells and their Defa4-expressing 
precursors, although other cell types may also be affected. The 
Paneth cells that underwent apoptosis were exclusively of the 
abnormal morphology patterns. Therefore, the abnormal Paneth 
cells may undergo apoptosis; however, they may also revert to 
normal morphology once smoking is discontinued.
We focused on Atg16l1T300A, as a knockin model that possesses 
the same polymorphism as CD patients, providing a mechanistic 
advantage over the whole gene–knockout models in select cell 
types. Similar mouse models for Nod2 polymorphisms exist, but 
this allele is much less common in CD cohorts of European ances-
try (4). Other CD susceptibility genes associated with abnormal 
Paneth cells do not yet have mouse models of their respective 
genetic polymorphisms. In addition, while we have previously 
shown that Paneth cell defects are induced in hypomorphic Atg16l1 
mice after MNV infection, we are unable to yet identify such a link 
in CD patients (21). Even so, smoking is a clinically relevant envi-
ronmental trigger (23, 47). We show that the combination of rele-
vant host genetic and environmental factors can provide insight 
into disease pathogenesis and therapeutic targets, as has been 
recently demonstrated in studies such as those of nonalcoholic 
fatty liver disease (48, 49).
The majority of the microbiome studies on the effect of 
smoking have centered on the oral cavity microbiota (50). A 
recent population-based microbiome study showed that smoking 
status and history showed modest effect on Bray-Curtis distance 
without significant associations for individual species or path-
ways (51). A small cross-sectional study of CD patients showed 
that smoking is associated with reduced microbiota diversity, 
with reduced abundance of limited taxa at the genera level (52). 
Our in vivo study was consistent with these findings. Along with 
the failure of horizontal transmission of Paneth cell defects in 
cohousing experiments, our data strongly suggest that micro-
biota changes were not a cause of Paneth cell defects. Overall, 
this supports our working model (53) showing that Paneth cell 
defects promote dysbiosis only in the presence of active inflam-
mation. In addition, recent studies have suggested that necro-
ptosis modulates Paneth cell function (40, 41). In our study, 
smoking-induced Paneth cell defects in T300A mice were only 
rescued by apoptosis inhibition, but not necroptosis inhibition, 
suggesting that different injuries may elicit different predomi-
nant cell death responses.
The value of the unbiased global transcriptomics approach 
is highlighted by the identification of Pparg as a central mediator 
in the T300A-smoking patterns, a finding that was not deducible 
from examining the effect of each single factor alone. PPARg has 
been shown to be downregulated in smoking-associated emphy-
sema (54), suggesting that the modulation of this pathway by 
smoking is likely a general tissue response. In addition, Pparg is 
linked to reduced Paneth cell numbers in mice fed a high-fat diet 
(38). Given that agents targeting this pathway (e.g., rosiglitazone) 
ment prevented Paneth cell defects (Figure 7A) and crypt apop-
tosis (Figure 7B). Anti–TNF-α administration did not alter the 
expression of genes involved in the PPARγ pathway (Supplemen-
tal Figure 21), suggesting that TNF-α acts downstream of PPARγ 
and mediates apoptosis induction. We further tested the role of 
TNF-α by crossing Atg16l1T300A mice to TNF receptor 1–deficient 
(Tnfr1–deficient) mice. Atg16l1T300A Tnfr1–/– mice were resistant to 
smoking-induced Paneth cell defects (Figure 7C) and crypt base 
apoptosis (Figure 7D). Therefore, the TNF-α–signaling pathway is 
a key mediator and therapeutic target for smoking-induced crypt 
apoptosis and Paneth cell defects in Atg16l1T300A mice.
Discussion
We previously showed that Paneth cell phenotypes are associ-
ated with CD genotypes, microbiota composition, a pathologic 
hallmark, unique transcriptomic profiles, and clinical outcome 
(11, 14, 15, 19, 20). However, clinically relevant environmental 
trigger or triggers and the mechanism or mechanisms driving 
Paneth cell defects were unclear (Figure 8A). In the current study, 
we show that relevant environmental stimuli can trigger Paneth 
cell defects in genetically susceptible hosts, confirming this phe-
Figure 7. Anti–TNF-α prevented Paneth cell defects. Administration of 
anti–TNF-α prevented smoking-induced (A) Paneth cell defects (P < 0.0001) 
and (B) crypt base apoptosis (P = 0.0011) in Atg16l1T300A mice. (A and B) 
Control, n = 9; anti–TNF-α, n = 10. Compared with the Atg16l1T300A mice, 
Atg16l1T300A Tnfr–/– mice exposed to cigarette smoking showed significantly 
(C) fewer Paneth cell defects (P = 0.0022) and (D) less crypt base apoptosis 
(P = 0.0087). (C and D) n = 6/group. Data were analyzed by Mann-Whitney U 
test. **P < 0.01; ****P < 0.0001. Data represent mean ± SEM.
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acid–binding proteins or fatty acid transporters, which would 
potentially involve liver-gut crosstalk (61).
In summary, we show that genetic and environmental fac-
tors synthesize to trigger unique biologic processes, resulting 
in a clinically relevant phenotype. Our data also provide com-
plementary mechanistic insights into the role of Paneth cells 
in mediating CD pathogenesis (16, 62) and identification of 
actionable therapeutic targets.
Methods
Study design. The overall objective of our study was to determine the 
associations between the ATG16L1T300A genotype and exposure to cig-
arette smoking in triggering Paneth cell defects. For human subjects, 
based on the prevalence of adult CD subjects harboring type I Paneth 
cell phenotype (14, 15) and the natural history of CD after resection (1), 
90 subjects were required to achieve a power of 80%. For in vivo exper-
iments, we used a previously described mouse strain (Atg16l1T300A) that 
is known to possess Paneth cell defects (28). Cigarette smoking was 
performed following a previously described protocol (63, 64), with the 
cigarette filters removed. Paneth cell analysis was performed using 
immunofluorescence (14, 15) on distal ileum. All the experiments were 
performed in several replicates over the course of 2 years. At least 3 to 
6 biological replicates were used for each group/experiment. The mice 
were randomized, and the investigator performing the histologic anal-
ysis was blinded to the sample identity. The design for microbiome 
studies included proper littermate controls and cohousing (65), and 
microbiome composition was analyzed using 16S rRNA-seq. Transcrip-
tomic analysis was performed using RNA-seq. All data were included 
(no outliers were excluded). Additional details, including the total 
numbers per study group, are included in the respective figure legends.
CD subjects. CD subjects who underwent ileocolectomy between 
1999 and 2010 at Washington University or Cedars-Sinai Medical Cen-
ter were previously described (14). A second CD cohort from Washing-
ton University composed of consecutive CD patients who underwent 
ileocolectomy between 2011 and 2013 were additionally included. 
Deidentified tissue samples from ileal resection margins that were free 
of acute inflammation were used for Paneth cell phenotype analysis.
The following information was retrieved from the medical record: 
sex, age at operation, smoking history (never smoker vs. active/
are readily available for routine clinical use, further clinical stud-
ies using these agents to treat CD patients who are smokers with 
Paneth cell defects will validate the importance of this pathway 
in CD. Furthermore, metabolic dysregulation is tightly connected 
with the TNF-α–associated apoptosis pathway. Therefore, pre-
viously recognized important genetic factors, an environmental 
factor, and inflammatory pathways converged to affect Paneth 
cell health and clinical prognosis. Of note, our complementary 
approaches (crypt base LCM, PC-Cre+ mice) support the tran-
scriptomics analysis from full-thickness ileum indicating that 
Paneth cells are the main target of the G+E effect.
Our data also suggest that smoking cessation may be ben-
eficial for ATG16L1T300A CD subjects with smoking-associated 
Paneth cell defects. Other potential intervention approaches 
include nicotine patch, PPARγ agonists, and anti–TNF-α. Anti–
TNF-α is a major treatment modality for CD (1), and rosigli-
tazone has been shown to be efficacious in ulcerative colitis 
(another major form of IBD) (55). Our data indicate that the 
Paneth cell phenotype may be used to stratify CD patients who 
may benefit from these therapies. One limitation of our study is 
that, due to the physical restraint of the smoking chamber, the 
cigarette-smoking experiments could not exceed 6 weeks. There-
fore, the effect of long-term cigarette smoking on Paneth cell 
defects, in particular the reversibility of the approaches described 
above, is unclear. In addition, while neither nicotine, lung pathol-
ogy, nor systemic inflammatory signals were shown to affect 
Paneth cells in this model, it is possible that the changes in gut 
transcriptomics and subsequent Paneth cell defects are the results 
of processes initiated external to the diseased/target organ (gut), 
similar to what occurs in rheumatoid arthritis (56), in which cig-
arette smoking has been shown to alter transcriptomic changes 
of the joints (57). One such possibility could be the lung-gut axis, 
such that cigarette smoking affects the lung on a molecular level 
(potentially through lung microbiome and/or metabolites) (58, 
59), which may in turn affect gut transcriptomics. In addition, the 
PPARγ pathway has best been studied in liver, skeletal muscle, and 
adipocytes in the context of metabolism (60). For example, based 
on the known PPARγ upstream regulatory mechanisms, we also 
speculate that the combination of G+E could affect either fatty 
Figure 8. Previous and current models of G+E 
resulting in Paneth cell defects. (A) Previous 
knowledge suggests G+E interaction may lead to 
Paneth cell defects, but the mechanisms have been 
unclear. (B) Proposed mechanistic model based on 
the current study. Clinically relevant genetic and 
environmental factors of CD could interact and 
induce metabolism dysfunction (defective PPARγ 
signaling), leading to TNF-α–mediated crypt base 
apoptosis and Paneth cell defects.
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age of total abnormal Paneth cells in the sample. The type I Paneth cell 
phenotype was defined as 20% or more of total Paneth cells showing 
abnormal morphology patterns, whereas the type II Paneth cell phe-
notype was defined as less than 20% of total Paneth cells showing 
morphologic defects (14).
Statistics. Clinical outcome correlation was performed using 
log-rank test. For analysis between different genotype and smok-
ing exposure combinations, Kruskal-Wallis tests followed by Dunn’s 
tests between groups were performed. For Paneth cell phenotype and 
various cellular readout comparisons in mouse experiments, 2-way 
ANOVA followed by Tukey’s multiple comparison adjustment was 
used. For microbiome studies, principle coordinate analysis was per-
formed using analysis of similarities (ANOSIM) with 999 permuta-
tions. Relative operational taxonomic unit (OTU) abundance data were 
input into linear discriminant analysis effect size (LEfSe) to determine 
biomarkers with significant linear discriminant analysis effect size (67). 
The determination of sample size and data analysis for animal studies 
followed the general guideline of Festing and Altman (68). Based on 
the law of diminishing returns, Mead recommended that a degree of 
freedom (DF) of 10 to 20 associated with error term in an ANOVA 
would be adequate to estimate preliminary information (69). All tests 
were 2 tailed, and a P value of less than 0.05 was considered significant. 
Data were plotted and analyzed using GraphPad Prism (version 6.05) 
and SAS version 9.4 (SAS Institute). Data represent mean ± SEM.
Study approval. The study was approved by the institutional review 
boards of Washington University School of Medicine and Cedars- 
Sinai Medical Center. Subjects provided written, informed consent. 
The animal studies were approved by the ethical committee at Wash-
ington University School of Medicine.
Data and materials availability. All Atg16l1T300A mouse study 
full-thickness ileal RNA-seq data were deposited in the EMBL-EBI’s 
ArrayExpress database (E-MTAB-5707). All Atg16l1T300A mouse 
study LCM-procured Paneth cell microarray data were deposited in 
the ArrayExpress database (E-MTAB-6168). All 16s rRNA-seq data 
for Atg16l1T300A mice were deposited in the ArrayExpress database 
(E-MTAB-5717). All 16s rRNA-seq data for the cohousing experiment 
were deposited in the ArrayExpress database (E-MTAB-5720).
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